A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : pVL / plasma viral load

[Related PubMed/MEDLINE]
Total Number of Papers: 226
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   pVL  (>> Co-occurring Abbreviation)
Long Form:   plasma viral load
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 10-year outcome of temporary structured treatment interruption (STI) among HIV-1-infected patients: An observational study in a single medical center. ART, PI, STI
2020 A Highly Prevalent Polymorphism in the Core Region Impairs Quantification of Hepatitis B Virus (HBV) by the cobas TaqMan HBV Assay. CTM, HBV, RTH
2020 Addressing Syndemics and Self-care in Individuals with Uncontrolled HIV: An Open Trial of a Transdiagnostic Treatment. ---
2020 An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy. cART
2020 Anti-toxoplasmic Immunoglobulin G Quantitation Correlates with Immunovirological Parameters of HIV-Infected Cameroonians. anti-Toxo IgG, PLHIV, RLS
2020 Antiretroviral therapy and detection of high-grade cervical intraepithelial neoplasia (CIN2+) at post-CIN management follow-up among women living with HIV: a systematic review and meta-analysis. aHR, aRR, ART, cOR, WLHIV
2020 Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis. AIN, ART, HAART, HR, OR
2020 Early and Successful Combination Antiretroviral Therapy Normalizes Survival Time in Patients Coinfected With Human Immunodeficiency Virus and Human T-cell Lymphotrophic Virus Type 1. cART, HIV, HTLV-1
2020 Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma. ART, CVL, IQR, WIHS
10  2020 HIV coinfections with tuberculosis among HIV-1 infected individuals in old cross river state, Nigeria. HIV, TB
11  2020 HIV-1 low-level viremia affects T cell activation rather than T cell development in school-age children, adolescents, and young adults during antiretroviral therapy. ART, VF, VS
12  2020 Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study. cART, CLHIV, LLV, PYFU, VF
13  2020 Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control. DMPs, ISGs, Tfh
14  2020 The interaction between detectable plasma viral load and increased body mass index on hypertension among persons living with HIV. AP, BMI, PLWH, RERI
15  2020 Unraveling HIV-1 diagnosis in special pediatric cases. ---
16  2019 A Tat/Rev Induced Limiting Dilution Assay to Measure Viral Reservoirs in Non-Human Primate Models of HIV Infection. MS, NHP
17  2019 Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study. DR
18  2019 Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood-brain barrier damage. BBB, CRT, CSF, NA
19  2019 Copy-Years Viremia and Risk of Virological Failure in Long-Term-Treated HIV Patients. ART, IQR, TD, VCY, VF
20  2019 Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). ---
21  2019 Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression. NRTIs, PI
22  2019 Emerging Patterns in HIV-1 gp120 Variable Domains in Anatomical Tissues in the Absence of a Plasma Viral Load. ---
23  2019 iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. APC, cART, caTLR4, DCs, HTI, WFI
24  2019 Impact of the frequency of plasma viral load monitoring on treatment outcomes among children with perinatally acquired HIV. cART, CLWH
25  2019 Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis. ART, CVD, MI, RR
26  2019 Shigellosis outbreak among MSM living with HIV: a case-control study in Taiwan, 2015-2016. aOR, MSM
27  2019 Similar efficacy and safety of dolutegravir between age groups of HIV-1-infected paediatric and young adult patients aged 5years and older. ---
28  2019 Therapeutic drug monitoring of darunavir/ritonavir in pregnancy. DRV, PK, PP, TDM
29  2019 Time to viral load suppression and its associated factors in cohort of patients taking antiretroviral treatment in East Shewa zone, Oromiya, Ethiopia, 2018. ART, CD4, HIV, IBM
30  2019 Travel-related health events and their risk factors in HIV-infected sub-Saharan migrants living in France and visiting their native country: The ANRS VIHVO cohort study. cART, SSA
31  2019 Virological remission after antiretroviral therapy interruption in female African HIV seroconverters. ART, PHI
32  2018 Association between HIV genotype, viral load and disease progression in a cohort of Thai men who have sex with men with estimated dates of HIV infection. ---
33  2018 CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication. CD4 count
34  2018 Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2017). ART
35  2018 High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy. GT
36  2018 High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C. ARV, MVC, PLHIV
37  2018 High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort. GSS
38  2018 Higher prevalence of viral control in HIV-1-infected women in serodiscordant relationships. ART, FDC, FSW
39  2018 HLA Class I-Mediated HIV-1 Control in Vietnamese Infected with HIV-1 Subtype A/E. CTLs
40  2018 Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals. ART, cART
41  2018 Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control. ---
42  2018 Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study. cART, cARV, cHIV, HIV, hu-BLT, NPs
43  2018 Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study. cART, NNRTIs, NRTIs, RAMs
44  2018 Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. CCR5, CI, ITT, MARCH, MVC
45  2018 Whole genome sequencing in the search for genes associated with the control of SIV infection in the Mauritian macaque model. nsSNPs
46  2017 A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study. POC
47  2017 Accumulation of Pol Mutations Selected by HLA-B*52:01-C*12:02 Protective Haplotype-Restricted Cytotoxic T Lymphocytes Causes Low Plasma Viral Load Due to Low Viral Fitness of Mutant Viruses. CTL, CTLs
48  2017 Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study. ART, DRMs, IF, NRTI, TAMs
49  2017 CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. cART
50  2017 Cost-effective HIV-1 virological monitoring in resource-limited settings using a modified commercially available qPCR RNA assay. ART, qPCR
51  2017 Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. ARV, HAART, IQR, ITT
52  2017 Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study. ---
53  2017 Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy. aHR
54  2017 Reactivation of HIV-1 proviruses in immune-compromised mice engrafted with human VOA-negative CD4+ T cells. ART, LRAs, NSG, VOA
55  2017 Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression. cART, HNUS
56  2017 Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. STR
57  2016 A strong association of human leukocyte antigen-associated Pol and Gag mutations with clinical parameters in HIV-1 subtype A/E infection. HLA-APs
58  2016 Application of Radial Basis Function Network Tool for Correlation of CD4+ Count with Plasma Viral Load in HIV-Seropositive Individuals. HIV, RBF
59  2016 Barriers to Viral Suppression Among Female Sex Workers: Role of Structural and Intimate Partner Dynamics. AOR, ART, CI, DTP, SWs
60  2016 CD4 T-Cell Responses in Primary HIV Infection: Interrelationship with Immune Activation and Virus Burden. ART, BL, PHI
61  2016 Detectable HIV Viral Load in Kenya: Data from a Population-Based Survey. ART, HIV, IQR
62  2016 Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. ---
63  2016 Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function. ABC, ART, eGFR, IQR, TDF
64  2016 Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016). ART, INSTI, NNRTI, NRTI
65  2016 Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. ---
66  2016 Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study. AOR, AOR, AOR, HAART
67  2016 First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load. cART, HIV
68  2016 High level of virological suppression among HIV-infected adults receiving combination antiretroviral therapy in Addis Ababa, Ethiopia. cART
69  2016 HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads. cART, CNS, CSF, NNAB
70  2016 Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings. BC, bPI, cART, NNRTI
71  2016 Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study. ATV, CI, HR, VF
72  2016 Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study. cART, VCY, VCY-e, VCY-l, VCY-o
73  2016 Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study. ART, PWID
74  2016 Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines. ART, DRMs, HIVDR, WHO
75  2016 Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model. hu-BLT, ISH, p.i, PLGA, PrEP, PT, T/F, TFV, TMS, vRNA
76  2016 Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. 2 patients, ATI, cART, PBMCs, pts
77  2015 Clinical outcome of HIV viraemic controllers and noncontrollers with normal CD4 counts is exclusively determined by antigen-specific CD8+ T-cell-mediated HIV suppression. IFN-gamma, NC, VC
78  2015 Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. ART
79  2015 Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). ART, INSTI, NNRTI, NRTI
80  2015 Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals. Gag-Pro RC
81  2015 Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. ART, GALT, LN, LTs, R/F
82  2015 Monotherapy with boosted PIs as an ART simplification strategy in clinical practice. TF, VF
83  2015 Twelve-Month Antiretroviral Therapy Suppresses Plasma and Genital Viral Loads but Fails to Alter Genital Levels of Cytokines, in a Cohort of HIV-Infected Rwandan Women. ART, GVL, HIV, STIs
84  2015 Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment. RR, VCY
85  2014 Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: a longitudinal study. ART
86  2014 Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. ---
87  2014 Differential partial activation phenotype and production of tumour necrosis factor-alpha by conventional dendritic cells in response to lipopolysaccharide in HIV+ viraemic subjects and HIV+ controllers. cDC, CTs, LPS, PBMCs, sCD14, ssRNA40, TNF
88  2014 Host-specific adaptation of HIV-1 subtype B in the Japanese population. CTL, HLA-APs
89  2014 Longitudinal comparison of HIV-1 plasma viral load and cellular proviral load. ART, PBMCs, WBC
90  2014 Optimization of PCR for quantification of simian immunodeficiency virus genomic RNA in plasma of rhesus macaques (Macaca mulatta) using armored RNA. aRNA, bDNA, qPCR, vRNA
91  2014 Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. ART, GSS, LLV
92  2014 Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure. ART
93  2014 Suboptimal plasma HIV-1 RNA suppression and adherence among sex workers who use illicit drugs in a Canadian setting: an observational cohort study. aOR, ART, SW-DU
94  2014 The spectrum of HIV mother-to-child transmission risk. cART, GA, MTCT
95  2014 Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010. ART, BC
96  2013 An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy. CI, HAART, HR, VF
97  2013 Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. CDC, CfE, HIV, MOH
98  2013 Disease progression and antiretroviral therapy in newly seropositive HIV subjects in a tertiary care hospital in North India. ART, HAART
99  2013 Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. ADRs, ART, HIV, ZDV
100  2013 Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania. ---